Advertisement

Topics

JPMorgan Cazenove provides wrong medicine for Shire, downgrading its rating to ‘neutral’

06:32 EST 20 Feb 2018 | Proactive Investors

JPMorgan's analysts said: “Valuation remains undemanding, but with few 2018 or 2019 catalysts beyond a potential NeuroScience spin, which we do not see creating fundamental value, we struggle to see outperformance this year”

Original Article: JPMorgan Cazenove provides wrong medicine for Shire, downgrading its rating to ‘neutral’

NEXT ARTICLE

More From BioPortfolio on "JPMorgan Cazenove provides wrong medicine for Shire, downgrading its rating to ‘neutral’"

Advertisement
Quick Search
Advertisement
Advertisement